Cardiac catheterization 3 to 24 hours after thrombolytic completion in STEMI patients.

Cardiac catheterization less than 3 hours after thrombolytic completion in STEMI patients.

ST-segment Elevation Myocardial Infarction (STEMI)

Cardiac catheterization by forearm approach 3 to 24 hours after thrombolytic completion in STEMI patients

Cardiac catheterization standard strategy

Cardiac catheterization by forearm approach within 3 hours after thrombolytic completion in STEMI patients

Cardiac catheterization fast strategy

Sancta Maggiore Hospital

Fast Radial Pharmaco-invasive Strategy In ST Elevation Myocardial Infarction Trial

Comparison Of The Fast Pharmaco-invasive Strategy With The Standard Pharmaco-invasive Strategy In Patients With ST Elevation Myocardial Infarction Stratified By The Forearm Approach: Randomized Clinical Trial

Mean Hemoglobin change 24 hours after the cardiac catheterization

Patients with Final coronary minimum luminal diameter greater than 30% and / or final coronary flow TIMI 0 or 1 after percutaneous coronary intervention

Composite of death from all cause, and major bleeding (BARC 3 or 5) during hospitalization

Number of participants with hemoglobin change over 3 g/dL

Target vessel quantitative flow ratio (QFR) before the percutaneous coronary intervention. This software measures the coronary flow after the procedure.

Target vessel quantitative flow ratio (QFR) after the percutaneous coronary intervention. This software measures the coronary flow after the procedure.

Patients with ischemic or hemorrhagic stroke during hospitalization: loss of neurological function caused by an ischemic or hemorrhagic event with residual symptoms lasting at least 24 hours after onset or leading to death

Patients with overt bleeding plus hemoglobin drop of 3 to < 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding

Patients with overt bleeding plus hemoglobin drop > 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents

Patients with intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision

Definite fatal bleeding (overt or autopsy or imaging confirmation)

New myocardial infarction during hospitalization: following the National Cardiovascular Data Registry (NCDR) criteria

Recurrent angina during hospitalization: new angina after 6 hours of pci until discharge

Number of participants with new or worsening heart failure during hospitalization: unusual dyspnea on light exertion, recurrent dyspnea occurring in the supine position, fluid retention; or the description of rales, jugular venous distension, pulmonary edema on physical exam, or pulmonary edema on chest x-ray

Number of participants with cardiogenic shock during hospitalization: episode of systolic blood pressure <90 mm Hg, and/or cardiac index <2.2 L/min/m2 determined to be secondary to cardiac dysfunction for at least 30 minutes, and/or the requirement for parenteral inotropic or vasopressor agents or mechanical support (e.g., Intra aortic balloon pump (IABP), extracorporeal circulation, ventricular assist devices) to maintain blood pressure and cardiac index above those specified levels.

Number of participants with readmission after 30 days of index event

Number of participants with new revascularization of the target vessel during hospitalization

University of Sao Paulo General Hospital

Comparison of the fast pharmaco-invasive strategy with the standard pharmaco-invasive strategy in patients with ST-elevation myocardial infarction stratified by the forearm approach

Egg Allergy

CHU Sainte-Justine

Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in a Population Allergic to Eggs

Pilot Project on Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in the Context of Influenza Vaccination in a Population Allergic to Eggs.

consciousness disorders/ödəm

Fast Radial Pharmaco-invasive Strategy In ST Elevation Myocardial Infarction Trial

Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in a Population Allergic to Eggs

Long Term Outcomes of EV71 CNS Infection

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası